Chinese biotech firm New Horizon Health shines in Hong Kong debut

New Horizon Health

18/02/2021 01:51

** Shares of Chinese biotech group New Horizon Health Ltd
 6606.HK  trade as high as HK$79.60 each in Hong Kong trading
debut, up 198.6% from their IPO price
    ** Zhejiang-based co's stock last up 168% from IPO price of
HK$26.66; the second most actively traded by turnover in early
trade
    ** The developer of screening products for colorectal and
cervical cancer sold 76.6 mln shares in Hong Kong IPO, raising
HK$2.04 bln ($263.1 mln) for commercialization, R&D and
expansion of product portfolio  urn:newsml:reuters.com:*:nFWN2KM0ZF
    ** The Hong Kong Hang Seng Commerce & Industry Index  .HSNC 
edges down 0.1%
    ** The Hang Seng China Enterprises index  .HSCE  slips 0.5%,
and the benchmark index  .HSI  falls 0.6%

($1 = 7.7525 Hong Kong dollars)

 (Reuters Messaging: donny.kwok.thomsonreuters.com@reuters.net)